Anti-C5 Aptamer for Dry AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry age-related macular degeneration (AMD) and geographic atrophy (GA) secondary to dry AMD are lacking, leading to significant visual impairment and blindness, with no approved therapies available for dry AMD, posing a major public health concern as the elderly population grows.
Innovation Solution
Administration of an anti-C5 agent, specifically a C5-specific aptamer conjugated with polyethylene glycol, to reduce or inhibit the activity of the C5 complement protein, thereby slowing or reversing the progression of dry AMD and GA, including reducing drusen formation and atrophy of retinal pigment epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is provided for dry AMD, then current visual impairment and blindness rates remain high, but there are no approved therapies to improve vision
Solution Approach 1:
The patent changes the complement system parameter by targeting C5 protein activity. The anti-C5 agent modifies the complement cascade progression, specifically inhibiting the conversion of C5a to C5b, thereby altering the harmful complement-mediated damage to retinal pigment epithelial cells and photoreceptors in dry AMD and geographic atrophy
Solution Approach 2:
The C5 protein acts as an intermediary in the complement cascade that causes damage in dry AMD. By targeting C5 specifically, the patent interrupts the harmful intermediary mechanism that leads to cell death and tissue atrophy, without affecting other complement components or pathways
2Stability of the object's composition
If C5 complement protein activity is reduced, then progression of dry AMD and GA is slowed, but complement system function may be compromised
Solution Approach 1:
The patent applies local quality by specifically targeting C5 protein activity in the retinal tissue context. The anti-C5 agent provides localized inhibition at the C5 step of the complement cascade within the eye, allowing selective modulation of complement function to protect retinal structures without completely shutting down complement-mediated immune surveillance
Solution Approach 2:
The patent uses partial action by inhibiting only the C5 conversion step rather than blocking the entire complement system. This partial inhibition is sufficient to prevent the harmful C5b-C9 membrane attack complex formation that causes retinal damage, while allowing other complement functions to remain operational
3Manufacturing precision
If anti-C5 agent is administered, then visual acuity is stabilized and GA growth is reduced, but treatment complexity increases
Solution Approach 1:
The patent extracts the harmful C5 protein activity from the complement cascade by using a specific anti-C5 agent. This extraction approach isolates and targets only the problematic C5 function that drives GA progression, separating it from the rest of the complement system's beneficial functions
Solution Approach 2:
The anti-C5 agent uses aaptamer-based molecular copy that mimics the structure and function of natural complement regulators. The aptamer sequence is designed to bind C5 with high affinity, creating a functional copy that inhibits C5 activity without requiring complex protein structures or multiple treatment components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-C5 agent effectively reduces the growth rate of GA lesions, stabilizes visual acuity, and decreases drusen formation, providing a therapeutic benefit for patients with dry AMD and GA, with statistically significant reductions in lesion area and improvements in visual acuity.
Implementation Method 1
Administration of an anti-C5 agent, specifically a C5-specific aptamer conjugated with polyethylene glycol, to reduce or inhibit the activity of the C5 complement protein
Data Source
AI summary
This invention relates to methods and compositions useful for treatment of subjects with dry age-related macular degeneration or geographic atrophy secondary to dry age-related macular degeneration. The methods involve administration of a pharmaceutical composition comprising an anti-C5 agent ARC1905, which comprises a C5-specific aptamer conjugated to a polyethylene glycol moeity via a linker, in an amount effective for slowing or inhibiting loss of low luminance visual acuity in the subject. The aptamer consists of the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T, wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine. Dosages and administration schedules are disclosed.